Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.00M | 2.13M | 2.33M | 2.01M | 2.80M | 2.31M |
| Gross Profit | 581.41K | 876.96K | -337.00K | -1.00M | 1.31M | 873.73K |
| EBITDA | -1.34M | -1.51M | -2.16M | -4.53M | -3.26M | -2.72M |
| Net Income | -1.76M | -1.90M | -4.04M | -5.37M | -3.63M | -2.40M |
Balance Sheet | ||||||
| Total Assets | 906.41K | 2.52M | 4.13M | 8.07M | 11.92M | 14.11M |
| Cash, Cash Equivalents and Short-Term Investments | 384.92K | 106.17K | 192.48K | 1.10M | 3.16M | 5.14M |
| Total Debt | 151.70K | 74.85K | 4.28K | 492.39K | 1.01M | 584.31K |
| Total Liabilities | 489.30K | 1.30M | 1.01M | 1.14M | 1.74M | 1.12M |
| Stockholders Equity | 417.11K | 1.22M | 3.12M | 6.93M | 10.19M | 12.99M |
Cash Flow | ||||||
| Free Cash Flow | -981.28K | -1.11M | -1.65M | -3.80M | -2.51M | -3.48M |
| Operating Cash Flow | -1.50M | -1.11M | -1.65M | -3.77M | -2.24M | -3.16M |
| Investing Cash Flow | 2.61M | 874.27K | 498.46K | -26.05K | -263.38K | -557.11K |
| Financing Cash Flow | -836.59K | 146.37K | 240.69K | 1.74M | 529.43K | 8.51M |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
51 Neutral | AU$18.76M | ― | ― | -5.86% | 98.26% | ||
42 Neutral | AU$5.10M | ― | -76.28% | ― | 5.01% | 74.84% | |
36 Underperform | AU$9.03M | ― | -548.03% | ― | 192.34% | 68.06% | |
34 Underperform | AU$8.62M | ― | -105.17% | ― | -3.82% | 51.47% | |
| €2.86M | ― | ― | ― | ― | |||
31 Underperform | AU$3.70M | ― | ― | -16.29% | 58.77% |
EVE Health Group Limited Corporate Events
EVE Health Group Limited has announced the quotation of 902,766 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of a transaction previously announced and could potentially impact the company’s market presence by increasing its liquidity and accessibility for investors.
EVE Health Group has successfully completed its Share Purchase Plan (SPP), allowing eligible shareholders to purchase new fully paid ordinary shares at $0.036 per share, the same price as a recent placement. The company received applications totaling $32,500, resulting in the issuance of 902,766 new shares, which will rank equally with existing shares, potentially strengthening its financial position and shareholder base.
EVE Health Group Limited has entered into a national prescribing agreement with TeleDocs Clinic for its oral soluble film for erectile dysfunction and gummy formulation for dysmenorrhea. This strategic partnership will enable EVE to leverage TeleDocs’ extensive network of over 3,500 pharmacies across Australia, enhancing product launch plans and patient access ahead of regulatory approvals. The collaboration will also involve practitioner education, digital integration, and promotional support, positioning EVE for a successful national rollout of its products.
EVE Health Group has announced a live investor webinar to update shareholders and investors on its strategy following the acquisition of Nextract Pty Ltd. The webinar will feature Mr. Damian Wood, the incoming CEO, who will discuss the company’s development pipeline and focus areas post-acquisition, as well as upcoming commercial and regulatory milestones. This event signifies EVE’s proactive approach to engaging with its stakeholders and highlights its strategic direction in the health industry.
EVE Health Group Limited has announced that Alasdair Cooke and several associated entities have ceased to be substantial holders in the company as of June 12, 2025. This change, primarily due to dilution, affects a significant number of fully paid ordinary shares and may impact the company’s ownership structure and voting dynamics.
EVE Health Group Limited has announced that Stuart Gunzburg has become a substantial holder in the company as of June 12, 2025, with a 19.38% voting power through various entities. This development could potentially influence the company’s strategic decisions and shareholder dynamics, given the significant voting power now held by Gunzburg.
EVE Health Group Limited has announced the appointment of Stuart Gunzburg as a director, effective June 12, 2025. Gunzburg holds significant interests in the company, including 7,936,508 ordinary shares directly and additional shares through entities where he serves as director or shareholder. This appointment and Gunzburg’s substantial shareholding may influence the company’s strategic direction and stakeholder confidence.
EVE Health Group Limited has completed the acquisition of Nextract Pty Ltd, a biotech company specializing in solubility-enhancing drug delivery systems. This strategic move positions EVE to expand its presence in the regulated healthcare sector, particularly targeting the erectile dysfunction and dysmenorrhea markets with innovative dosage formats. The acquisition was settled through the issuance of shares, and a $1 million placement was completed to fund Nextract’s integration and initial manufacturing scale-up. The company also announced significant board and management changes, including the appointment of Dr. Stuart Gunzburg as Chief Scientific Officer and Executive Director, and the transition of Mr. Bill Fry to a Non-Executive Director role. This acquisition and leadership restructuring are expected to accelerate EVE’s growth and enhance its market positioning.
EVE Health Group Limited has announced the quotation of 113,444,444 ordinary fully paid securities on the ASX, effective June 12, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with the company’s growth strategy.
EVE Health Group Limited has issued a prospectus for several offers, including Placement Shares, Nextract Vendors Shares, Lead Manager Shares, and SPP Shares, all priced at 3.6 cents per share. This transaction-specific prospectus, prepared under section 713 of the Corporations Act, is aimed at raising capital through the ASX for the company’s ongoing operations, with implications for investors to consider the suitability of these securities in light of their own financial circumstances.
EVE Health Group Limited announced a significant change in the director’s interest in securities due to a consolidation of shares. The consolidation, approved at the company’s General Meeting, reduced the number of shares held by Director Gregory William Fry and his related entities, impacting the overall share distribution and potentially affecting the company’s market positioning and shareholder value.
EVE Health Group has completed a share consolidation on a forty-to-one basis, as approved by shareholders. This move results in a new capital structure with 131,862,715 ordinary shares. The consolidation aims to streamline the company’s capital structure, potentially enhancing its market position and operational efficiency. Trading on a normal T+2 settlement basis will resume on 12 June 2025.
EVE Health Group has commenced stability testing for its new oral products aimed at treating erectile dysfunction and dysmenorrhea, marking a significant step towards regulatory approval in Australia. These products, developed by Nextract, use proven active pharmaceutical ingredients in novel dissolvable formats for improved patient experience. The testing is a critical part of the regulatory submission process, with approvals anticipated by the end of 2025. This development aligns with EVE’s strategy to target high-value, under-served markets with unmet clinical needs, leveraging Australia’s regulatory pathways to accelerate access to prescription medicines. Additionally, EVE has completed its registration with the Therapeutic Goods Administration as a sponsor and manufacturer, further advancing its health and wellness strategy.
EVE Health Group announced that all resolutions at their General Meeting were passed, including the acquisition of Nextract Pty Ltd. This acquisition will lead to leadership changes, with Mr. Stuart Gunzburg joining the Board and Mr. Damian Wood becoming the CEO. The integration of Nextract is expected to enhance EVE’s expansion into regulated pharmaceutical markets, potentially strengthening its industry position and offering new opportunities for stakeholders.
Eve Health Group Limited is focusing on reformulating a drug targeting the erectile dysfunction market, which is valued at $5.3 billion. The new formulation aims to enhance solubility for faster action and higher efficacy, potentially impacting the company’s operations and market positioning by tapping into a significant market segment.
EVE Health Group Limited has requested a trading halt on its securities pending the announcement of the results from a general meeting. This meeting will consider a transaction under ASX Listing Rule 11.1, and the trading halt will remain until the results are disclosed, impacting the company’s market activities and potentially its strategic direction.
EVE Health Group Limited has announced its acquisition of Nextract, an Australian biotech company specializing in advanced oral delivery systems for regulated health markets. This strategic move allows EVE to enter the global erectile dysfunction and dysmenorrhea markets, valued at $5.3 billion and $10.9 billion respectively. The acquisition, valued at $3 million in equity, is supported by a capital raising plan and a 40:1 share consolidation. The integration of Nextract’s capabilities is expected to enhance EVE’s technical expertise and broaden its strategic initiatives. The company is targeting regulatory submissions for Nextract’s lead products by late 2025, with commercial launches anticipated in Q4 2025. The acquisition also positions EVE to tap into the MENA region’s growing demand for high-quality, alcohol-free health products.
EVE Health Group Limited has announced a security consolidation for its ordinary fully paid securities, which will commence trading on a deferred settlement basis from June 2, 2025. This move is part of the company’s strategic efforts to reorganize its securities, with the consolidation requiring security holder approval, which was obtained on May 29, 2025.
EVE Health Group Limited has announced an update to its previous announcement regarding the proposed issue of securities. The update includes a revised timetable for the securities offer under a securities purchase plan, which is part of the company’s strategy to enhance its market presence and operational capabilities.
EVE Health Group Limited has announced a General Meeting for its shareholders, scheduled for May 29, 2025, in Subiaco, WA. The company will not send hard copies of the meeting notice, aligning with modern digital practices, and encourages shareholders to access the notice online. This move reflects the company’s commitment to sustainability and digital transformation, potentially impacting shareholder engagement and operational efficiency.
EVE Health Group Limited has announced a General Meeting scheduled for May 29, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate either in person or by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This meeting is significant for stakeholders as it provides an opportunity to engage with the company’s strategic direction and decisions.
EVE Health Group Limited has announced its acquisition of Nextract Pty Ltd, an Australian biotech firm specializing in novel pharmaceutical and nutraceutical delivery systems. This strategic move allows EVE to enter the $5.3 billion erectile dysfunction market and the $10.9 billion dysmenorrhea market with Nextract’s innovative, alcohol-free, orally dissolvable strips and chewable formats. The acquisition is valued at $3 million in equity, supported by a $1.5 million capital raising, and aims to expedite EVE’s entry into regulated markets, leveraging streamlined regulatory pathways in Australia. The acquisition is expected to enhance EVE’s market positioning, open new revenue streams, and offer high-margin potential through proprietary IP, with commercial launch targeted for Q4 2025.